Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.

F

Fundacion Universitaria Maria Cano

Status

Enrolling

Conditions

Neuropathic Pain

Treatments

Device: Repetitive transcranial magnetic stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT05480410
013008028-2021-311

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness of Repetitive transcranial magnetic stimulation (rTMS) on pain and quality of life in patients with cancer neuropathic pain. Although there are currently different therapeutic options for neuropathic pain, most are limited or restricted to pharmacotherapy. Transcranial magnetic stimulation (TMS) is a tool recently incorporated into neuroscience in the management of neuropathic cancer pain. The study will include 10 patients with oncologic neuropathic pain who will receive 20 sessions of rTMS and the effect on pain and quality of life.

Full description

Neuropathic pain is defined as pain caused by a primary lesion or transient dysfunction of the central or peripheral nervous system. In cancer, it is generated as a consequence of multiple factors such as: direct compression of nerve structures, post-surgical nerve injuries, and nerve injuries secondary to chemotherapy. At least 3.5 million people around the world suffer from this symptom associated with cancer; Of this population, 38% experience pain in all stages and 80% in advanced stages, negatively impacting quality of life.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with neuropathic pain of oncological origin
  • Patients of legal age (18 years old)
  • Patients using their cognitive faculties

Exclusion criteria

  • Pregnancy
  • History of negative reaction to TMS
  • History of seizure, history of epilepsy stroke, brain surgery and cranial metal implants.

Trial design

10 participants in 1 patient group

Active intervention
Experimental group
Description:
Patients will receive 20 sessions of transcranial magnetic stimulation applied with the MagVenture Mag Pro R20 equipment, these sessions will be held daily from Monday to Friday, lasting 20 minutes at an intensity of 81% with a motor threshold of 90 A/ns.
Treatment:
Device: Repetitive transcranial magnetic stimulation

Trial contacts and locations

0

Loading...

Central trial contact

Isabel Angel, MSc; Catalina Lopera, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems